Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin oral - Oramed Pharmaceuticals

Drug Profile

Insulin oral - Oramed Pharmaceuticals

Alternative Names: Orally ingestible insulin capsule - Oramed Pharmaceuticals; ORMD-0801

Latest Information Update: 07 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oramed Pharmaceuticals
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 17 Oct 2019 Oramed initiates enrolment in a phase II trial for Type 1 diabetes mellitus in USA (NCT04150107)
  • 03 Jul 2019 Oramed Pharmaceuticals and Hefei Tianhui Incubator of Technologies plans clinical trials in China (PO)
  • 21 May 2019 Oramed Pharmaceuticals completes enrolment in its phase IIb HbA1c trial for Type 2 diabetes mellitus in USA (PO) (NCT03467932)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top